Lipids, lipoprotein (a) and coronary artery disease in patients following cardiac transplantation

Transpl Int. 1996;9(5):481-5. doi: 10.1007/BF00336826.

Abstract

Cardiac allograft vascular disease (CAVD) is the most important cause of late mortality in cardiac transplant recipients. While the pathogenesis of the disease is believed to be immunological, other factors like hyperlipidaemia may contribute. Total cholesterol, LDL cholesterol. HDL cholesterol, triglycerides, apolipoprotein A1 and B and Lp(a) levels were measured in 174 cardiac transplant recipients attending our clinic for routine follow-up. Univariate and multivariate logistic regression analysis was carried out to assess the relationship of the variables studied to the presence of CAVD diagnosed with coronary angiography. CAVD was present in 42 of the 174 patients. The group with CAVD had a higher total cholesterol (6.8 vs 6.3 mmol/l), lower HDL cholesterol (0.8 vs 0.9 mmol/l), higher triglyceride (2.8 vs 2.0 mmol/l) and higher Lp(a) level (317.5 vs 95 mg/l) than the group without CAVD. In multivariate analysis, after adjusting for gender, hypertension, time from transplantation, preoperative diagnosis and lipid-lowering therapy, Lp(a), total cholesterol, HDL cholesterol and triglycerides remained significantly correlated with CAVD. The results indicate a significant association between hyperlipidaemia, Lp(a) levels and allograft vascular disease. Further studies are needed to show whether treatment of hyperlidaemia in this population delays the onset or slows the progression of CAVD.

MeSH terms

  • Adult
  • Comorbidity
  • Coronary Disease / epidemiology*
  • Cytomegalovirus Infections / epidemiology
  • Diabetes Mellitus / epidemiology
  • Endothelium, Vascular / immunology
  • Endothelium, Vascular / pathology
  • Female
  • Follow-Up Studies
  • Heart Transplantation*
  • Humans
  • Hyperlipidemias / epidemiology
  • Hypertension / epidemiology
  • Incidence
  • Lipids / blood*
  • Lipoprotein(a) / blood*
  • Male
  • Middle Aged
  • Postoperative Complications / epidemiology*
  • Risk Factors

Substances

  • Lipids
  • Lipoprotein(a)